tcda-20210506
false000159558500015955852021-05-062021-05-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2021
https://cdn.kscope.io/e408c7dad27675f8f8a540a695e7ed7b-tcda-20210506_g1.jpg
TRICIDA, INC.
(Exact name of Registrant as specified in its charter)

Delaware

001-38558

46-3372526
(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)
7000 Shoreline Court
Suite 201
South San Francisco, CA 94080
(Address of principal executive offices) (Zip Code)
(415) 429-7800
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading Symbol(s)Name of exchange on which registered
Common stock, par value $0.001 per shareTCDAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company






If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02Results of Operations and Financial Condition.
On May 6, 2021, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its first quarter ended March 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On April 27, 2021, the Company announced that it will host a conference call and webcast at 4:30 pm Eastern Time, on May 6, 2021, during which the Company will discuss its financial results for the first quarter ended March 31, 2021 and report its business progress.
Item 9.01Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit Number Description
   
99.1 
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
 







SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.






Dated: May 6, 2021

TRICIDA, INC.






By:

/s/ Geoffrey M. Parker


Name:

Geoffrey M. Parker


Title:

Chief Operating Officer, Chief Financial Officer and Executive Vice President




Document

Exhibit 99.1
https://cdn.kscope.io/e408c7dad27675f8f8a540a695e7ed7b-tricidalogoa031.jpg
FOR IMMEDIATE RELEASE
Tricida Announces First Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time
SOUTH SAN FRANCISCO, Calif., May 6, 2021 — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2021 and provided an update on key initiatives.
Recent Events
Tricida continues to execute on recruitment and conduct of the VALOR-CKD renal outcomes trial. As of May 4, 2021, the VALOR-CKD renal outcomes trial has randomized 1,440 of 1,600 subjects with an average treatment duration of approximately 15 months and has accrued 95 of the 511 required subjects with a positively adjudicated primary endpoint event, defined as the time to first occurrence of renal death, end-stage renal disease (ESRD) or a confirmed greater than or equal to 40% reduction in eGFR (DD40).
Tricida sponsored several presentations at the National Kidney Foundation Spring Clinical Meeting 2021 that occurred April 6 to 10, 2021, including analyses of: 1) the association between metabolic acidosis and accelerated kidney decline, 2) the association in kidney transplant recipients between metabolic acidosis and graft failure and 3) the association in kidney transplant recipients between metabolic acidosis and a higher risk of death. In addition, Tricida presented in vitro data showing that veverimer does not bind to, or affect the ion binding properties of, other non-absorbed binder drugs that are prescribed to patients with CKD, such as RENVELA, VELTASSA, LOKELMA and KAYEXALATE.
Tricida previously announced that it received an Appeal Denied Letter (ADL) from the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) in response to its Formal Dispute Resolution Request (FDRR). Tricida intends to continue execution of the ongoing VALOR-CKD renal outcomes trial and believes that the optimal path forward for the potential approval of veverimer is to provide additional data to the FDA from the VALOR-CKD renal outcomes trial.



Upcoming Milestones
Anticipate the first VALOR-CKD renal outcomes trial interim analysis for early stopping for efficacy in the second half of 2021, when 150 patients with DD40 events are expected to have accrued. If the independent unblinded Interim Analysis Committee does not recommend stopping the trial early for efficacy, Tricida will receive no information from this interim analysis.
Anticipate the second VALOR-CKD renal outcomes trial interim analysis for early stopping for efficacy in mid-2022, when 250 patients with DD40 events are expected to have accrued. If the independent unblinded Interim Analysis Committee does not recommend stopping the trial early for efficacy, Tricida will receive no information from this interim analysis.
“Our VALOR-CKD trial is our key focus this year,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “The timing of accrual of primary endpoint events in the VALOR-CKD trial is an important measure moving forward as it will impact our options for next steps in veverimer’s development given our current financial resources.”
Financial Results for the Three Months Ended March 31, 2021
Research and development expense was $32.2 million and $49.4 million for the three months ended March 31, 2021 and 2020, respectively. The decrease in research and development expense for the three months ended March 31, 2021 compared to the prior year was primarily due to decreased activities in connection with our veverimer clinical development program related to manufacturing process optimization and the manufacturing of drug substance and lower personnel costs.
General and administrative expense was $9.9 million and $23.5 million for the three months ended March 31, 2021 and 2020, respectively. The decrease in general and administrative expense for the three months ended March 31, 2021 compared to the prior year was primarily due to decreased administrative activities in connection with our veverimer clinical development program, including pre-commercialization, medical affairs and personnel costs.
Net loss was $53.4 million (non-GAAP net loss of $38.3 million) and $74.1 million (non-GAAP net loss of $63.8 million) for the three months ended March 31, 2021 and 2020, respectively. Net loss per basic and diluted share was $1.06 and $1.49 for the three months ended March 31, 2021 and 2020, respectively.
As of March 31, 2021, cash, cash equivalents and investments were $217.7 million.
Financial Guidance
Tricida believes it has financial resources to fund its planned operations into late 2022. Based on the current rate of primary endpoint events in the VALOR-CKD renal outcomes trial, the first and second interim analyses for early stopping of the trial are expected to occur within the time frame of our existing capital.
Tricida Conference Call Information
Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast today at 4:30 pm Eastern Time. The webcast or conference call may be accessed as follows:



Tricida Conference Call
Thursday, May 6, 2021
4:30 pm Eastern Time
Webcast:    IR.Tricida.com
Dial-In:    (877) 377-5478
International:    (629) 288-0740
Conference ID:    9047649

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. There are no FDA-approved treatments for chronic metabolic acidosis. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, all of the statements under the heading “Upcoming Milestones” and “Financial Guidance” and other statements, including the Company’s plans and expectations regarding event accrual rates for the VALOR-CKD renal outcomes trial, its plans for interactions and communications with the FDA, its plans and expectations as to the pathway to approval of veverimer by the FDA, if at all, and its expectations regarding financial runway are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, without limitation, the timing of the FDA’s approval of veverimer, if at all; the potential availability of the Accelerated Approval Program and the approvability of veverimer under that program; the Company’s plans and expectations with regard to its interactions with the FDA, including the potential resubmission of an NDA for veverimer; the Company’s plans and expectations for future clinical and product development milestones; the Company’s contractual and financial obligations to our its key suppliers and vendors; the Company’s financial projections and cost estimates; risks associated with the COVID-19 pandemic; and risks associated with the Company’s business prospects, financial results and business



operations; risks related to the Company’s ability to retain its key employees and executives; and risks related to the Company’s capital requirements and ability to raise sufficient funds for its operations. These and other factors that may affect the Company’s future business prospects, results and operations are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report filed on Form 10-K. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

(Financial Tables to Follow)



Tricida, Inc.

Condensed Balance Sheets
(Unaudited)
(In thousands)
March 31,
2021
December 31, 2020
Assets
Current assets:
Cash and cash equivalents$40,510 $137,857 
Short-term investments177,221 171,670 
Prepaid expenses and other current assets2,989 4,488 
Total current assets220,720 314,015 
Long-term investments— 22,757 
Property and equipment, net1,053 1,112 
Operating lease right-of-use assets13,395 13,801 
Total assets$235,168 $351,685 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$5,321 $3,508 
Current operating lease liabilities2,341 2,079 
Accrued expenses and other current liabilities32,543 28,671 
Total current liabilities40,205 34,258 
Term Loan, net— 76,638 
Convertible Senior Notes, net120,775 118,670 
Non-current operating lease liabilities12,627 13,046 
Other long-term liabilities— 202 
Total liabilities173,607 242,814 
Stockholders’ equity:
Preferred stock— — 
Common stock50 50 
Additional paid-in capital748,712 742,555 
Accumulated other comprehensive income (loss)(41)64 
Accumulated deficit(687,160)(633,798)
Total stockholders’ equity61,561 108,871 
Total liabilities and stockholders’ equity$235,168 $351,685 




Tricida, Inc.

Condensed Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share amounts)
 Three Months Ended
March 31,
 20212020
Operating expenses:
Research and development$32,175 $49,381 
General and administrative9,895 23,526 
Total operating expenses42,070 72,907 
Loss from operations(42,070)(72,907)
Other income (expense), net445 813 
Interest expense(5,613)(2,020)
Loss on early extinguishment of Term Loan(6,124)— 
Net loss(53,362)(74,114)
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale investments, net of tax(105)(232)
Total comprehensive loss$(53,467)$(74,346)
Net loss per share, basic and diluted$(1.06)$(1.49)
Weighted-average number of shares outstanding, basic and diluted50,247,698 49,841,407 






Tricida, Inc.

GAAP to non-GAAP reconciliations
(Unaudited)
(In thousands)
A reconciliation between net loss on a GAAP basis and on a non-GAAP basis is as follows:
 Three Months Ended
March 31,
 20212020
GAAP net loss, as reported$(53,362)$(74,114)
Adjustments:
Non-cash operating lease costs248 320 
Accretion of Term Loan and Convertible Senior Notes2,628 751 
Loss on early extinguishment of Term Loan6,124 — 
Stock-based compensation6,042 8,374 
Changes in fair value of compound derivative liability(202)846 
Restructuring costs220 — 
Total adjustments15,060 10,291 
Non-GAAP net loss$(38,302)$(63,823)
Use of Non-GAAP Financial Measures
We supplement our financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss and diluted earnings per share, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss” is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss adjusted to exclude (1) non-cash operating lease costs, (2) accretion of Term Loan and Convertible Senior Notes, (3) loss on early extinguishment of Term Loan, (4) stock-based compensation, (5) changes in fair value of compound derivative liability, and (6) restructuring costs (cash and non-cash), in reconciling of our GAAP to Non-GAAP net loss. Non-GAAP financial measures used by Tricida may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

#####

Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of
Investor Relations and Communications
IR@Tricida.com